Compare PGY & MESO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PGY | MESO |
|---|---|---|
| Founded | 2016 | 2004 |
| Country | United States | Australia |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.8B |
| IPO Year | N/A | N/A |
| Metric | PGY | MESO |
|---|---|---|
| Price | $21.85 | $19.50 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 2 |
| Target Price | ★ $39.86 | $24.00 |
| AVG Volume (30 Days) | ★ 2.5M | 247.0K |
| Earning Date | 02-12-2026 | 08-28-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,245,946,000.00 | $17,198,000.00 |
| Revenue This Year | $28.75 | $576.59 |
| Revenue Next Year | $17.23 | $41.15 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 28.33 | ★ 191.39 |
| 52 Week Low | $8.27 | $9.61 |
| 52 Week High | $44.99 | $22.00 |
| Indicator | PGY | MESO |
|---|---|---|
| Relative Strength Index (RSI) | 40.60 | 65.75 |
| Support Level | $22.72 | $19.00 |
| Resistance Level | $24.06 | $19.90 |
| Average True Range (ATR) | 1.31 | 0.55 |
| MACD | 0.01 | 0.09 |
| Stochastic Oscillator | 16.63 | 85.20 |
Pagaya Technologies Ltd is a financial technology company working to reshape the lending marketplace by using machine learning, data analytics, and sophisticated AI-driven credit and analysis technology. It was built to provide a comprehensive solution to enable the credit industry to deliver customers a positive experience while simultaneously enhancing the broader credit ecosystem. Its proprietary API seamlessly integrates into its next-gen infrastructure network of partners to deliver a premium customer user experience and greater access to credit. The company generates majority of its revenue from United States.
Mesoblast Ltd is a commercial-stage biotechnology company and a world leader in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The company's product candidates include: Ryoncil (remestemcel-L) for the treatment of steroid-refractory acute graft versus host disease, as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of an adult stem cell technology platform for commercialization.